Legal Representation
Attorney
John L. Slafsky
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 10, 2023 | MAB2 | E | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | Loading... |
| May 10, 2023 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| May 10, 2023 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Oct 26, 2022 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Oct 26, 2022 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Oct 26, 2022 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Sep 29, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Sep 28, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Sep 28, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Apr 18, 2022 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Apr 18, 2022 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
| Apr 18, 2022 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Mar 22, 2022 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 22, 2022 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 22, 2022 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 7, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 7, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 7, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 6, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 12, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 15, 2021 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations used by investigators and researchers and neurologists for diagnosing and treating diseases of the central nervous system; none of the foregoing related to atazanavir
First Use Anywhere:
0
First Use in Commerce:
0
Class 042
scientific research, pharmaceutical research, medical research, technical consultation and product development for investigators and researchers and neurologists in the field of development of pharmaceuticals for neurodegenerative diseases; none of the foregoing related to atazanavir
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
042